The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The ClearBridge Small Cap Growth Strategy generated strong absolute returns of over 21% gross but underperformed its Russell 2000 Growth Index benchmark, which gained 25.6% in the second quarter. The quarter saw exceptional performance driven by AI enthusiasm, with investors seeking exposure across memory, optical, networking and high-performance compute capacity. The Strategy benefited from AI-exposed semiconductor holdings like Allegro MicroSystems and Lattice Semiconductor, as well as infrastructure enablers like Bloom Energy. However, idiosyncratic weakness in select health care and financial holdings, software pressure from AI disruption concerns, and under-exposure to high-beta, high-momentum AI stocks limited relative performance. The managers added 13 new positions during an unusually large Russell rebalance, including Axsome Therapeutics in biotechnology, MaxLinear in semiconductors, and Solaris Energy Infrastructure to capture data center power demand. Looking forward, they see potential for continued small cap outperformance as the AI opportunity extends beyond infrastructure builders to companies using AI effectively, though they acknowledge rapid disruption and geopolitical volatility create a complicated backdrop. Their bottom-up discipline focuses on separating durable growth from temporary momentum.
The ClearBridge Small Cap Growth Strategy seeks to identify small cap companies with durable, distinctive growth drivers and the capacity to invest in significant opportunities, maintaining bottom-up discipline to separate durable growth from temporary momentum even as market narratives move faster than fundamentals.
The managers see potential for continued small cap outperformance given investor appetite for undiscovered growth stories, innovation, an AI investment cycle with related opportunities and risks, and a possible cyclical recovery. They note that the next phase of opportunity may extend beyond companies building AI infrastructure to companies using AI effectively across transportation, biotechnology, financial services and other industries. However, they acknowledge that debates around AI capital spending and which elements of the supply chain capture the most economic return will persist, and leadership can change quickly as narratives often move faster than fundamentals. Their bottom-up discipline is designed to separate durable growth from temporary momentum in this environment.
As of Jul 15, 2026
Lead Portfolio Manager
Aram Green
Managing Partner
Moderate Conviction Bullish
Market Conviction
The Strategy demonstrates moderate-high conviction through specific position sizing language and named holdings with clear theses. The managers explicitly discuss individual positions like Allegro MicroSystems, Lattice Semiconductor, Bloom Energy, and Varonis Systems with specific performance drivers. They added 13 new positions with articulated rationales, including detailed explanations for Axsome Therapeutics, MaxLinear, and Solaris Energy Infrastructure. However, the portfolio appears diversified across multiple sectors and themes rather than concentrated, and the managers acknowledge the challenging environment for active management. The specificity of holdings and willingness to act during the rebalance supports a score above 0.65, but the breadth of positions and hedged language around market dynamics prevents a higher score.
Growth Outlook
Market outlook remains moderate conviction: The ClearBridge Small Cap Growth Strategy outperformed its benchmark in a highly volatile Q1 2026 by leveraging strong stock selection in industrials and defensively navigating the...
Risk Appetite
Risk appetite posture is above average conviction: The ClearBridge Small Cap Growth Strategy outperformed its benchmark in a highly volatile Q1 2026 by leveraging strong stock selection in industrials and defensively navigating the...
Capital Deployment
The Strategy added 13 new positions during the quarter while exiting only 5, representing net deployment activity. This demonstrates active capital allocation and willingness to put money to work during the Russell rebalance. However, no specific cash level changes are disclosed, and the activity appears to be largely rotation-driven rather than a significant reduction in cash reserves. The managers describe robust new idea generation and selective deployment rather than aggressive across-the-board capital deployment. The net addition of 8 positions suggests moderate deployment activity, scoring in the moderate positive range.
Forward Guidance
Forward guidance signal: The ClearBridge Small Cap Growth Strategy outperformed its benchmark in a highly volatile Q1 2026 by leveraging strong stock selection in industrials and defensively navigating the...
Language Signal
The letter contains meaningful bullish language around AI opportunities, small cap recovery potential, robust new idea generation, and attractive valuations. Terms like strong gains, material gains, encouraging, and potential appear frequently. However, this is balanced by substantial risk language including disruption concerns, challenging backdrop, complicated macroeconomic environment, unsettled policy, and pressure on software holdings. The managers emphasize discipline, selectivity, and the difficulty of the current environment for active management. The net balance leans modestly positive but is far from overwhelmingly bullish.
Perceived Risk
Perceived risk level is evaluated as above average conviction. The ClearBridge Small Cap Growth Strategy outperformed its benchmark in a highly volatile Q1 2026 by leveraging strong stock selection in industrials and defensively navigating the...
Opportunity Density
The managers describe robust new idea generation and added 13 new positions during the quarter, suggesting they are finding attractive opportunities. They see potential for continued small cap outperformance and note that the next phase of AI opportunity may extend beyond infrastructure to companies using AI effectively across multiple industries. They characterize the Russell rebalance as creating opportunities with biotechnology representation increasing materially. However, they also emphasize the need for selectivity and discipline, noting that many of the strongest-performing benchmark areas are segments that disciplined bottom-up investors approach with selectivity. This suggests a selective rather than broadly abundant opportunity set, scoring in the moderate-positive range.
Time Horizon
The managers demonstrate a multi-year investment horizon with emphasis on durable, distinctive growth drivers and the capacity to invest in significant opportunities. They describe holding Insmed as a long-standing biotech position and express confidence in meaningful long-term peak sales potential despite near-term weakness. The focus on separating durable growth from temporary momentum and the willingness to hold through volatility suggests a 2-5 year thesis timeframe. However, the letter also discusses quarterly performance drivers, near-term catalysts like drug launches and clinical data, and specific events like the Russell rebalance, indicating some attention to medium-term milestones. The balance suggests a multi-year but not decade-plus horizon, scoring in the upper-moderate range.
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with ClearBridge Investments Small Cap Growth Strategy or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.
